Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
04 2019
Historique:
received: 04 11 2018
accepted: 17 01 2019
pubmed: 24 1 2019
medline: 27 2 2020
entrez: 24 1 2019
Statut: epublish

Résumé

Voriconazole is a first-line antifungal agent. Therapeutic drug monitoring is a standard of care. The best way to adjust dosages to achieve desired drug exposure endpoints is unclear due to nonlinear and variable pharmacokinetics. Previously described software was used to prospectively adjust voriconazole dosages. The

Identifiants

pubmed: 30670416
pii: AAC.02353-18
doi: 10.1128/AAC.02353-18
pmc: PMC6496160
pii:
doi:

Substances chimiques

Antifungal Agents 0
Cytochrome P-450 Enzyme System 9035-51-2
Voriconazole JFU09I87TR

Banques de données

EudraCT
['2013-0025878-34']
ISRCTN
['ISRCTN83902726']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Department of Health
ID : CS/08/08/10
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Hope et al.

Références

Antimicrob Agents Chemother. 2015;59(6):3090-7
pubmed: 25779580
Ther Drug Monit. 2012 Aug;34(4):467-76
pubmed: 22722776
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60
pubmed: 27365388
Clin Microbiol Infect. 2014 Apr;20 Suppl 3:27-46
pubmed: 24548001
Antimicrob Agents Chemother. 2013 Apr;57(4):1888-94
pubmed: 23380734
Antimicrob Agents Chemother. 2011 Oct;55(10):4782-8
pubmed: 21768513
Antimicrob Agents Chemother. 2012 Jan;56(1):526-31
pubmed: 22064545
Lancet Infect Dis. 2014 Jun;14(6):498-509
pubmed: 24768475
J Antimicrob Chemother. 2014 May;69(5):1162-76
pubmed: 24379304
Clin Infect Dis. 2012 Oct;55(8):1080-7
pubmed: 22761409
Clin Infect Dis. 2010 Jan 1;50(1):27-36
pubmed: 19951112
Clin Infect Dis. 2008 Jan 15;46(2):201-11
pubmed: 18171251

Auteurs

William Hope (W)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom william.hope@liverpool.ac.uk.
Royal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom.

Gary Johnstone (G)

Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, United Kingdom.

Silvia Cicconi (S)

Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, United Kingdom.

Timothy Felton (T)

Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester Academic Health Science Centre, Wythenshawe, Manchester, United Kingdom.
Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom.

Joanne Goodwin (J)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Sarah Whalley (S)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Anahi Santoyo-Castelazo (A)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Virginia Ramos-Martin (V)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Jodi Lestner (J)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Leah Credidio (L)

Royal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom.

Aaron Dane (A)

Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
DaneStat Consulting, Macclesfield, United Kingdom.

Daniel F Carr (DF)

MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, United Kingdom.

Munir Pirmohamed (M)

Royal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom.
MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, United Kingdom.

Rahim Salim (R)

Royal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom.

Michael Neely (M)

Laboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH